- Home
- AII vs LRMR Comparison
AII vs LRMR Comparison
Compare AII & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AII | LRMR |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.6M | 455.8M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AII | LRMR |
|---|---|---|
| Price | $25.83 | $3.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $26.33 | $16.50 |
| AVG Volume (30 Days) | 199.2K | ★ 857.9K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | ★ 91.53 | N/A |
| EPS | ★ 2.76 | N/A |
| Revenue | ★ $276,485,000.00 | N/A |
| Revenue This Year | $35.92 | N/A |
| Revenue Next Year | $17.74 | $1,816.14 |
| P/E Ratio | $9.39 | ★ N/A |
| Revenue Growth | ★ 35.30 | N/A |
| 52 Week Low | $16.19 | $2.72 |
| 52 Week High | $27.00 | $6.42 |
Technical Indicators
Market Signals| Indicator | AII | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 44.77 |
| Support Level | $25.18 | $3.57 |
| Resistance Level | $27.00 | $4.21 |
| Average True Range (ATR) | 0.88 | 0.19 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 21.29 | 20.39 |
Price Performance
Historical ComparisonAbout AII American Integrity Insurance Group Inc.
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, North Carolina, South Carolina, and Georgia.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.